LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...

LOS ANGELES--(BUSINESS WIRE)--Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using ...

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging technology, is excited to announce the commencement of an observational study focused on characterizing early cognitive ...

Please provide your email address to receive an email when new articles are posted on . Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a ...

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S.

Bryan Johnson founded Kernel to offer neurodata acquisition and analytics services at an affordable price. Bryan Johnson says his “secret weapon” when it came to launching neurotech company Kernel was ...

Using Kernel's technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules ...